Trestle Biotherapeutics is developing bioengineered therapies for patients suffering from end stage renal disease (ESRD), aiming to provide implantable therapeutic tissues that can take patients off dialysis and delay the need for kidney transplants
Trestle Biotherapeutics is developing bioengineered therapies for patients suffering from end stage renal disease (ESRD), aiming to provide implantable therapeutic tissues that can take patients off dialysis and delay the need for kidney transplants.
Trestle Biotherapeutics is developing bioengineered therapies for patients suffering from end stage renal disease (ESRD), aiming to provide implantable therapeutic tissues that can take patients off dialysis and delay the need for kidney transplants
Trestle Biotherapeutics is developing bioengineered therapies for patients suffering from end stage renal disease (ESRD), aiming to provide implantable therapeutic tissues that can take patients off dialysis and delay the need for kidney transplants.